Reply to comments from Vincent et al.
Letter to the Editor
- 56 Downloads
- 1.Tamura K, Kawai Y, Kiguchi T et al (2016) Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol 21:996–1003CrossRefPubMedGoogle Scholar
- 6.The Japanese Societyof Medical Oncology (ed) (2013) Clinical practice guideline for tumor lysis syndrome. Kanehara Shuppan, TokyoGoogle Scholar
© Japan Society of Clinical Oncology 2017